These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 2492166)
21. The dexamethasone suppression test in inpatients with panic disorder or agoraphobia with panic attacks. Grunhaus L; Tiongco D; Haskett RF; Greden JF Biol Psychiatry; 1987 Apr; 22(4):517-21. PubMed ID: 3567265 [No Abstract] [Full Text] [Related]
22. Platelet serotonin uptake in panic disorder. Norman TR; Judd FK; Gregory M; James RH; Kimber NM; McIntyre IM; Burrows GD J Affect Disord; 1986; 11(1):69-72. PubMed ID: 2944930 [TBL] [Abstract][Full Text] [Related]
23. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Coplan JD; Papp LA; Martinez J; Pine D; Rosenblum LA; Cooper T; Liebowitz MR; Gorman JM Am J Psychiatry; 1995 Apr; 152(4):619-22. PubMed ID: 7694915 [TBL] [Abstract][Full Text] [Related]
26. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men. Hulse JA; Rosenthal SM; Cuttler L; Kaplan SL; Grumbach MM J Clin Endocrinol Metab; 1986 Oct; 63(4):872-8. PubMed ID: 3091629 [TBL] [Abstract][Full Text] [Related]
27. Basal adrenocortical activity and DST in electrodermally differentiated subgroups of panic patients. Kopp MS; Arató M; Magyar I; Buza K Int J Psychophysiol; 1989 Mar; 7(1):77-83. PubMed ID: 2925467 [TBL] [Abstract][Full Text] [Related]
28. [The dexamethasone suppression test in agoraphobia with panic attacks. 30 cases]. Cottraux J; Claustrat B Encephale; 1984; 10(6):267-72. PubMed ID: 6529933 [TBL] [Abstract][Full Text] [Related]
29. Short term continuous intravenous infusion of growth hormone (GH) inhibits GH-releasing hormone-induced GH secretion: a time-dependent effect. Rosenthal SM; Kaplan SL; Grumbach MM J Clin Endocrinol Metab; 1989 Jun; 68(6):1101-5. PubMed ID: 2498383 [TBL] [Abstract][Full Text] [Related]
30. A 3H-flunitrazepam binding inhibitor is present in psychiatric patients' sera. Marazziti D; Pietrini P; Martini C; Giannaccini G; Perugi G; Placidi GF; Cassano GB; Lucacchini A Neuropsychobiology; 1987; 18(2):74-6. PubMed ID: 2836759 [TBL] [Abstract][Full Text] [Related]
31. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion. Kelijman M; Frohman LA J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420 [TBL] [Abstract][Full Text] [Related]
32. Growth hormone response to growth hormone-releasing hormone and clonidine in young monkeys: correlation with behavioral characteristics. Coleman K; Dahl RE; Ryan ND; Cameron JL J Child Adolesc Psychopharmacol; 2003; 13(3):227-41. PubMed ID: 14642012 [TBL] [Abstract][Full Text] [Related]
33. Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH. Bamberger CM; Mönig H; Mill G; Gödde E; Schulte HM Exp Clin Endocrinol Diabetes; 1995; 103(3):205-8. PubMed ID: 7584524 [TBL] [Abstract][Full Text] [Related]
37. Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls. Gann H; Riemann D; Stoll S; Berger M; Müller WE Pharmacopsychiatry; 1995 May; 28(3):80-3. PubMed ID: 7568369 [TBL] [Abstract][Full Text] [Related]